Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33159646&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients #MMPMID33159646
Hariharan A; Hakeem AR; Radhakrishnan S; Reddy MS; Rela M
Inflammopharmacology 2021[Feb]; 29 (1): 91-100 PMID33159646show ga
Coronavirus disease 2019 (COVID-19) pandemic has affected health care systems worldwide. Severe presentations of COVID-19 such as severe pneumonia and acute respiratory distress syndrome (ARDS) have been associated with the post-viral activation and release of cytokine/chemokines which leads to a "cytokine storm" causing inflammatory response and destruction, mainly affecting the lungs. COVID-19 activation of transcription factor, NF-kappa B (NF-kappaB) in various cells such as macrophages of lung, liver, kidney, central nervous system, gastrointestinal system and cardiovascular system leads to production of IL-1, IL-2, IL-6, IL-12, TNF-alpha, LT-alpha, LT-beta, GM-CSF, and various chemokines. The sensitised NF-kappaB in elderly and in patients with metabolic syndrome makes this set of population susceptible to COVID-19 and their worse complications, including higher mortality. Immunomodulation at the level of NF-kappaB activation and inhibitors of NF-kappaB (IkappaB) degradation along with TNF-alpha inhibition will potentially result in a reduction in the cytokine storm and alleviate the severity of COVID-19. Inhibition of NF-kappaB pathway has a potential therapeutic role in alleviating the severe form of COVID-19.
free
free
free
Inflammopharmacology 2021 ; 29 (1): 91-100
